Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1393–1416 of 1,581 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Type 1 Diabetes (T1D) Clear all
Completed No phase listed Observational

Use of CoG by Patients With Diabetes Mellitus

NCT03840161
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
non-invasive tissue glucose prediction
Device
Lead sponsor
Sciema UG
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Evaluation of the Accuracy of an Implanted Glucose Sensor

NCT02647905
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Continuous Glucose Monitoring System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
9
States / cities
Concord, California • Escondido, California • Walnut Creek, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

NCT04270942
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
teplizumab 1 mg/mL
Drug
Lead sponsor
Provention Bio, a Sanofi Company
Industry
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
8
States / cities
Aurora, Colorado • New Haven, Connecticut • Gainesville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Omnipod 5 System Compared to Pump Therapy

NCT05409131
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Omnipod 5 System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 70 Years
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
10
States / cities
Palo Alto, California • Santa Barbara, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Effect of Medium Chain Fatty Acids on Cognitive Function During Acute Hypoglycemia in Patients With Type 1 Diabetes

NCT00592072
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Medium chain fatty acid (Octanoic and Decanoic acid), Splenda (Placebo Control)
Dietary Supplement · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 16, 2026, 10:04 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

A Clinical Trial Assessing the Impact of Inhaled Insulin on Glucose Disposition

NCT00287066
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Inhaled Human Insulin, Regular Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Oct 16, 2026, 10:04 PM EDT
Recruiting Phase 2 Interventional

ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes

NCT04933851
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
ACT1VATE, DSME/S
Behavioral
Lead sponsor
Scripps Whittier Diabetes Institute
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 1 Interventional

Subcutaneous Pharmacokinetic Evaluation of Monomeric Insulin and Lyumjev in Adults With Type 1 Diabetes

NCT07090824
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Type 1 Diabetes Mellitus
Interventions
Diluted Humalog U-200 Insulin, Diluted U-500 Humulin Insulin, Lyumjev U-100 Insulin, Boost Mixed Meal Test
Drug · Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 16, 2026, 10:04 PM EDT
Completed No phase listed Observational

Support Group Surveys for Individuals Who Have Type 1 Diabetes and an Eating Disorder

NCT00818142
View directory record Official record
Conditions
Eating Disorder, Type 1 Diabetes
Interventions
ED/DM Support Group
Behavioral
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced Oct 16, 2026, 10:04 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

NCT06305286
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation with Tegoprubart (AT-1501) immunosupression-based therapy
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 2 Interventional Results available

BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes

NCT01498185
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo matching Dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
12
States / cities
Chula Vista, California • San Diego, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Not applicable Interventional

Internet-Based Cognitive Behavioral Therapy for Depressive Symptoms in Adolescents With Type 1 Diabetes Mellitus

NCT03655067
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Depressive Symptoms
Interventions
CATCH-IT
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 17 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 16, 2026, 10:04 PM EDT
Withdrawn Not applicable Interventional

Effects of a Remote Patient Monitoring Protocol on Glycemic Control in Adolescents With Type 1 Diabetes

NCT03466398
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes Mellitus
Interventions
Vivify Health RPM Protocol
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
13 Years to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 14, 2020 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Use of Control-IQ Technology 2.0 in Adults, Children, and Preschoolers With Type 1 Diabetes

NCT05683392
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
t:slim X2 insulin pump with Control-IQ technology 2.0
Device
Lead sponsor
Tandem Diabetes Care, Inc.
Industry
Eligibility
2 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Not applicable Interventional

A Prospective, Randomized, Parallel Crossover Study Demonstrating Subject Wearability and Usability of the I-Port Injection Port

NCT00486109
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
I-Port(TM) Injection Port
Device
Lead sponsor
Patton Medical Devices
Industry
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
5
States / cities
Atlanta, Georgia • Omaha, Nebraska • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2008 · Synced Oct 16, 2026, 10:04 PM EDT
Recruiting Not applicable Interventional

CGM Academy for Youth With Type 1 Diabetes

NCT06408207
View directory record Official record
Conditions
Type1 Diabetes
Interventions
CGM Academy
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
8 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)

NCT03662334
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rapid Acting insulin with pre-treatment of rHuPH20, Sham injection
Drug · Device
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 1, 2019 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 1 Interventional Results available

T1DM Immunotherapy Using CD4+CD127lo/-CD25+ Polyclonal Tregs

NCT01210664
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
San Francisco, California • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Insulin Delivery Using Microneedles in Type 1 Diabetes

NCT00837512
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Microneedle, Subcutaneous insulin catheter
Device
Lead sponsor
Emory University
Other
Eligibility
8 Years to 18 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2014 · Synced Oct 16, 2026, 10:04 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Thromboelastographic Profile in Healthy Newborns and Infants of Diabetic Mothers Using TEG6s

NCT04917965
View directory record Official record
Conditions
Thromboelastography, Coagulation; Fetus or Newborn, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes, Gestational
Interventions
Laboratory clotting studies
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
0 Hours to 2 Hours
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Not applicable Interventional Results available

Biobehavioral Mechanisms of Glucose Variability

NCT01835964
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Glucose Variability Observation
Procedure
Lead sponsor
University of Virginia
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes

NCT03740919
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
LY900014, Insulin Lispro, Insulin Glargine, Insulin Degludec
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
1 Year to 17 Years
Enrollment
751 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
27
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 16, 2026, 10:04 PM EDT
Completed Phase 4 Interventional Results available

Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis

NCT02078882
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
abatacept
Biological
Lead sponsor
Christopher Bowlus, MD
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2020 · Synced Oct 16, 2026, 10:04 PM EDT
Active, not recruiting Not applicable Interventional

Using Technology to Address Disparities and Promote Healthcare Equity in Type 1 Diabetes Registry

NCT06899984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Patient Navigator
Behavioral
Lead sponsor
University of Chicago
Other
Eligibility
14 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 16, 2026, 10:04 PM EDT